Could More Frequent Blood Testing Transform How We Detect Disease?
Notas del episodio
In this episode of Diagnosing Dx, David Filby is joined by Octavian Florescu, CEO of In Diagnostics.
An electrical engineer and microchip designer by training, Octavian has spent his career exploring how semiconductor technology can be applied to blood testing. After building and exiting his first diagnostics company, he took those lessons into In Diagnostics alongside his co-founder and wife, Ana.
Octavian explains how the company is developing microchip-based blood testing from a drop of blood, why they are launching first in the veterinary market, and how a two-person “minimum viable company” is working towards profitability before expanding further into human diagnostics.
We also discuss what founders learn when capital is scarce, why diagnostics may need different funding models, and how better access to longitudinal blood data could support more personalised healthcare.
Key takeaways:
🔹 Why Octavian believes blood testing should become more frequent and accessible
🔹 How lessons from his first diagnostics company shaped In Diagnostics
🔹 Why the veterinary market offers an early route to revenue and product validation
🔹 The thinking behind building a two-person “minimum viable company”
🔹 Why diagnostics funding may need to move beyond traditional venture timelines
Chapters:
01:02 Introduction and Octavian Florescu’s background
04:32 From microchip design to blood testing
06:33 Lessons from his first diagnostics company
11:20 Building In Diagnostics as a minimum viable company
13:52 Microchip-based blood testing and the unmet need for more data
19:15 Launching first in veterinary diagnostics
22:27 Building towards profitability without traditional VC funding
29:53 Upcoming milestones and the future of diagnostics
Guest: Octavian Florescu
CEO, In Diagnostics
LinkedIn: https://www.linkedin.com/in/octavian-florescu-51b28817/
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.